Signal detection of adverse reactions for bendamustine based on FDA adverse event reporting system

References

• Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clin Ther. 2009;31(2):2290–2311. doi: 10.1016/j.clinthera.2009.11.031
   PubMedGoogle Scholar
• Hakamifard A, Mardani M, Nasiri MJ, et al. Bendamustine and pneumocystis pneumonia: a systematic review. Health Sci Rep. 2022;5(3):e610. doi: 10.1002/hsr2.610
   PubMedGoogle Scholar
• Sakai R, Ohmachi K, Sano F, et al. Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study. Ann Hematol. 2019;98:2131–2138. doi: 10.1007/s00277-019-03750-7
   PubMed Web of Science ®Google Scholar
• Satoshi Y, Takumi M, Mariko M, et al. Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study. Ann Hematol. 2022;101(1):209–211. doi: 10.1007/s00277-020-04388-6
   PubMed Web of Science ®Google Scholar
• Tageja N. Bendamustine: safety and efficacy in the management of indolent non-Hodgkin's lymphoma. Clin Med Insights Oncol. 2011;5:145–156. doi: 10.4137/cmo.S6085
   PubMedGoogle Scholar
• Klippstein A, Schneider CP, Sayer HG, et al. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol. 2003;129(5):316–319. doi: 10.1007/s00432-003-0441-y
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57(3):512–519. doi: 10.3109/10428194.2015.1110748
   PubMed Web of Science ®Google Scholar
• Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin’s lymphoma: a practice guide for patient management. Oncology. 2013;18(8):954–964. doi: 10.1634/theoncologist.2013-0079
   Google Scholar
• Gafter-Gvili A, Gurion R, Raanani P, et al. Bendamustine-associated infections—systematic review and meta-analysis of randomized controlled trials. Hematol Oncol. 2017;35(4):424–431. doi: 10.1002/hon.2350
   PubMed Web of Science ®Google Scholar
• Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4–5):143–150. doi: 10.1016/j.blre.2010.06.004
   PubMed Web of Science ®Google Scholar
• Ahrens N, Genth R, Kiesewetter H, et al. Misdiagnosis in patients with diclofenac-induced hemolysis: new cases and a concise review. Am J Hematol. 2006;81(2):128–131. doi: 10.1002/ajh.20494
   PubMed Web of Science ®Google Scholar
• Goldschmidt N, Gural A, Ben-Yehuda D, et al. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2013;72(3):709–713. doi: 10.1007/s00280-013-2243-5
   PubMed Web of Science ®Google Scholar
• Wu TKY, Tang KHK, Hwang YY, et al. Bendamustine treatment of haematological malignancies: significant risks of opportunistic viral, fungal and bacterial infections. Hematology. 2022;27(1):535–542. doi: 10.1080/16078454.2022.2072065
   PubMed Web of Science ®Google Scholar
• Luca P, Valentina G, Bianca S, et al. Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens. Open Med (Wars). 2021;16(1):672–682. doi: 10.1515/med-2021-0274
   PubMedGoogle Scholar
• Noriyoshi I, Katsuhiro M, Hiromichi T, et al. Clinical entity of cytomegalovirus disease in patients with malignant lymphoma on bendamustine therapy: a single-institution experience. Leuk Lymphoma. 2023;64(1):171–177. doi: 10.1080/10428194.2022.2131426
   PubMed Web of Science ®Google Scholar
• Anat G, Elena R, Nadav M, et al. Infections associated with bendamustine containing regimens in hematological patients: a retrospective multi-center study. Leuk Lymphoma. 2016;57(1):63–69. doi: 10.3109/10428194.2015.1046862
   PubMed Web of Science ®Google Scholar
• Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to Bendamustine. Clin Infect Dis. 2019;68(2):247–255. doi: 10.1093/cid/ciy458
   PubMed Web of Science ®Google Scholar
• Tapan U, May SK, Fiore J, et al. Reactivation of hepatitis B virus following bendamustine-containing chemotherapy in a patient with multiple myeloma. Leuk Lymphoma. 2011;52(5):916–918. doi: 10.3109/10428194.2010.551573
   PubMed Web of Science ®Google Scholar
• Lock G, Helmich F, Bertram M. Impending liver failure after chemoimmunotherapy-induced reactivation of hepatitis B - successful treatment with entecavir. Dtsch Med Wochenschr. 2012;137(23):1248–1250. doi: 10.1055/s-0032-1305038
   PubMed Web of Science ®Google Scholar
• Yoshiki H, Akira K, Hirohisa S, et al. [Two cases of malignant lymphoma with reactivation of resolved hepatitis B virus infection after bendamustine hydrochloride monotherapy]. Nihon Shokakibyo Gakkai Zasshi. 2016;113(9):1582–1587. doi: 10.11405/nisshoshi.113.1582
   PubMedGoogle Scholar
• Angela R, Lorenzo R, Miriam L, et al. Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. J Antimicrob Chemother. 2012;67(2):510–511. doi: 10.1093/jac/dkr486
   PubMed Web of Science ®Google Scholar
• Uchida M, Kawashiri T, Maegawa N, et al. Pharmacovigilance evaluation of bendamustine-related skin disorders using the Japanese adverse drug event report database. J Pharm Pharm Sci. 2021;24:16–22. doi: 10.18433/jpps31597
   PubMed Web of Science ®Google Scholar
• Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25(2):225–234. doi: 10.1097/cad.0000000000000032
   PubMed Web of Science ®Google Scholar
• Rice MBJ, Thompson CA, Barreto JN, et al. Incidence of pneumocystis jirovecii pneumonia utilizing a polymerase chain reaction-based diagnosis in patients receiving bendamustine. Cancer Med. 2021;10(15):5120–5130. doi: 10.1002/cam4.4067
   PubMed Web of Science ®Google Scholar
• Bernard-Valnet R, Koralnik IJ, Pasquier DR. Advances in treatment of progressive multifocal leukoencephalopathy. Ann Neurol. 2021;90(6):865–873. doi: 10.1002/ana.26198
   PubMed Web of Science ®Google Scholar
• Trociukas I, Zirnis AE, Beļajeva L, et al. Progressive multifocal encephalopathy in a patient with non-Hodgkin follicular lymphoma. Exp Oncol. 2020;42(3):238–241. doi: 10.32471/exp-oncology.2312-8852.vol-42-no-3.15198
   PubMedGoogle Scholar
• Lane MA, Renga V, Pachner AR, et al. Late occurrence of PML in a patient treated for lymphoma with immunomodulatory chemotherapies, bendamustine, rituximab, and Ibritumomab Tiuxetan. Case Rep Neurol Med. 2015;2015:1–4. doi: 10.1155/2015/892047
   Google Scholar
• Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17(1):37–51. doi: 10.1038/s41582-020-00427-y
   PubMed Web of Science ®Google Scholar
• Pavlovic D, Patel MA, Patera AC, et al. T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy. Immunobiology. 2018;223(6–7):508–517. doi: 10.1016/j.imbio.2018.01.002
   PubMed Web of Science ®Google Scholar
• Aly L, Yousef S, Schippling S, et al. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome. Brain. 2011;134(9):2687–2702. doi: 10.1093/brain/awr206
   PubMedGoogle Scholar
• Gheuens S, Bord E, Kesari S, et al. Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol. 2011;85(14):7256–7263. doi: 10.1128/jvi.02506-10
   PubMed Web of Science ®Google Scholar